{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T07:48:55Z","timestamp":1763624935367,"version":"3.45.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.japh.2025.102924","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T12:51:22Z","timestamp":1757335882000},"page":"102924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Achievement of time in range goals among patients with diabetes using continuous glucose monitoring"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1200-4861","authenticated-orcid":false,"given":"Faezeh","family":"Azizi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9059-8787","authenticated-orcid":false,"given":"Katherine","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0798-6841","authenticated-orcid":false,"given":"Lauren","family":"Enser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7310-6880","authenticated-orcid":false,"given":"Samantha","family":"Heacock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.japh.2025.102924_bib1","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.japh.2025.102924_bib2","doi-asserted-by":"crossref","first-page":"828","DOI":"10.4093\/dmj.2020.0257","article-title":"Time in range from continuous glucose monitoring: a novel metric for glycemic control","volume":"44","author":"Yoo","year":"2020","journal-title":"Diabetes Metab J"},{"issue":"suppl 1","key":"10.1016\/j.japh.2025.102924_bib3","first-page":"S146","article-title":"7. Diabetes technology: standards of care in diabetes\u20142025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.japh.2025.102924_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2337\/dc19-0888","article-title":"Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow-up from the COMISAIR study","volume":"43","author":"\u0160oupal","year":"2020","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.japh.2025.102924_bib5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/jama.2016.19975","article-title":"Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical Trial","volume":"317","author":"Beck","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.japh.2025.102924_bib6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/M16-2855","article-title":"Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial","volume":"167","author":"Beck","year":"2017","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.japh.2025.102924_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2016.19976","article-title":"Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial","volume":"317","author":"Lind","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.japh.2025.102924_bib8","first-page":"15","article-title":"The role of the pharmacist in the management of type 2 diabetes: current insights and future directions","volume":"6","author":"Hughes","year":"2017","journal-title":"Integr Pharm Res Pract"},{"key":"10.1016\/j.japh.2025.102924_bib9","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.2147\/DMSO.S342936","article-title":"Pharmacist-managed diabetes programs: improving treatment adherence and patient outcomes","volume":"15","author":"Orabone","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"10.1016\/j.japh.2025.102924_bib10","doi-asserted-by":"crossref","DOI":"10.24926\/iip.v15i1.6081","article-title":"Clinical and financial outcomes of a pilot pharmacist-led continuous glucose monitoring clinic","volume":"15","author":"Ballard","year":"2024","journal-title":"Innov Pharm"},{"issue":"5","key":"10.1016\/j.japh.2025.102924_bib11","first-page":"600","article-title":"Effect of pharmacist-driven professional continuous glucose monitoring in adults with uncontrolled diabetes","volume":"26","author":"Sherrill","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"10.1016\/j.japh.2025.102924_bib12","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.japh.2023.07.010","article-title":"Pharmacist-driven continuous glucose monitoring in community and ambulatory care pharmacy practice: a scoping review","volume":"63","author":"Vascimini","year":"2003","journal-title":"J Am Pharm Assoc"},{"issue":"2","key":"10.1016\/j.japh.2025.102924_bib13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/19322968211049783","article-title":"Patient demographics and clinical outcomes among type 1 diabetes patients using continuous glucose monitors: data from T1D exchange real-world observational study","volume":"17","author":"DeSalvo","year":"2023","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"10.1016\/j.japh.2025.102924_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000809","article-title":"Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)","volume":"7","author":"Fokkert","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"2","key":"10.1016\/j.japh.2025.102924_bib15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2337\/dc19-1610","article-title":"Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study","volume":"43","author":"Charleer","year":"2020","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.japh.2025.102924_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/dme.15348","article-title":"Real time continuous glucose monitoring in high-risk people with insulin-requiring type 2 diabetes: a randomized controlled trial","volume":"41","author":"Lever","year":"2024","journal-title":"Diabet Med"},{"issue":"4","key":"10.1016\/j.japh.2025.102924_bib17","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1210\/clinem\/dgad652","article-title":"Effectiveness of continuous glucose monitoring on metrics of glycemic control in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"109","author":"Uhl","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.japh.2025.102924_bib18","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.2337\/dc19-1459","article-title":"Effects of continuous glucose monitoring on metrics of glycemic control in diabetes: a systematic review with meta-analysis of randomized controlled trials","volume":"43","author":"Maiorino","year":"2020","journal-title":"Diabetes Care"},{"issue":"22","key":"10.1016\/j.japh.2025.102924_bib19","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1001\/jama.2021.6530","article-title":"Association of real-time continuous glucose monitoring with glycemic control and acute metabolic events among patients with insulin-treated diabetes","volume":"325","author":"Karter","year":"2021","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.japh.2025.102924_bib20","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1001\/jama.2021.7444","article-title":"Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical Trial","volume":"325","author":"Martens","year":"2021","journal-title":"JAMA"},{"issue":"suppl 1","key":"10.1016\/j.japh.2025.102924_bib21","first-page":"S111","article-title":"6. Glycemic goals and hypoglycemia: standards of care in Diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.japh.2025.102924_bib22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/dia.2018.0310","article-title":"The relationship of hemoglobin A1C to time-in-range in patients with diabetes","volume":"21","author":"Vigersky","year":"2019","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"10.1016\/j.japh.2025.102924_bib23","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/1932296818822496","article-title":"The relationships between time in range, hyperglycemia metrics, and HbA1c","volume":"13","author":"Beck","year":"2019","journal-title":"J Diabetes Sci Technol"},{"issue":"6","key":"10.1016\/j.japh.2025.102924_bib24","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled Trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.japh.2025.102924_bib25","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/dom.12937","article-title":"Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)","volume":"19","author":"Pozzilli","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.japh.2025.102924_bib26","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154431912500603X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154431912500603X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T07:43:37Z","timestamp":1763624617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154431912500603X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S154431912500603X"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2025.102924","relation":{},"ISSN":["1544-3191"],"issn-type":[{"type":"print","value":"1544-3191"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Achievement of time in range goals among patients with diabetes using continuous glucose monitoring","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2025.102924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102924"}}